Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...

Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

The University of Naples Federico II inaugurates a world-class facility: the International Training Center for Medically ...

Doxycycline postexposure prophylaxis has the potential to substantially reduce real-world population-level incidence of ...

An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers ...

Co Inc (NYSE:MRK) shares, reducing the pharmaceutical giant's price target from $130.00 to $122.00 while reaffirming a Buy rating on the stock. The revision by Guggenheim analyst is primarily due to ...

Several foreign drugmakers have announced debuts for their new drugs in the Chinese market since the beginning of 2025, as ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

UnitedHealth Group (UNH) reported weaker-than-expected fourth quarter revenue due to weakness in its health insurance unit and soaring medical costs. Morning Brief hosts Brad Smith and Seana Smith ...